Premier's Perspective hospital-based database was used to assess mortality, length of stay, and cost for major esophagus, stomach, and bowel procedures in patients with and without candidemia (International Classification of Diseases, Ninth Revision, Clinical Modification, code 112.5, disseminated candidiasis). Candidemia was associated with a 63.8% higher extreme risk of mortality, 37.1% greater in-hospital mortality, 61.2% longer mean length of stay, and 55.4% higher total costs. Antifungal drugs represented 4.0% and 2.4% of the total costs for patients with and without candidemia, respectively. General linear model analysis indicated that candidemia was associated with a significant increase of $15,727 in total costs (t = 5.87; P < 0.0001); antifungal drugs represent a small percentage of these costs.
From the *Merck & Co, Inc, Whitehouse Station, NJ; †Med Data Analytics, Williamsville, NY; ‡Rutgers University, New Brunswick, NJ; §Baxter International, Deerfield, IL; and ∥Jefferson Medical College, Philadelphia, PA.
Reprints: Sheenu Chandwani, MPH, 1140 Oakcroft Lane, Somerset, New Jersey 08873. E-mail: email@example.com.
Data were presented at the European Congress for Chemotherapy Microbiology and Infectious Disease on April 2008, Barcelona, Spain.
Sheenu Chandwani, MPH, was an employee of Rutgers University, participating in a joint fellowship with Merck & Co, Inc. at the time of this study.
Robin Turpin was affiliated with Merck & Co., during the study development and analysis and that she is currently an employee of Baxter Healthcare.
This study was funded by Merck & Co, Inc.